Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOLA: osimertinib induction before chemoradiotherapy followed by maintenance osimertinib in EGFR-mutant unresectable stage III NSCLC
CTR20241401Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2024; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20241401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241401.